{"id":"W4380992939","doi":"10.1158/1078-0432.ccr-23-0797","title":"Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression","year":2023,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research; University of Toronto; University Health Network","funders":"Eisai; Seagen; Ontario Institute for Cancer Research; Novocure; Regeneron Pharmaceuticals; Princess Margaret Cancer Foundation; Genentech; PharmaMar; AstraZeneca","keywords":"Olaparib; PARP inhibitor; Ovarian cancer; Cancer research; Cancer; Medicine; Oncology; DNA; Pharmacology; Internal medicine; Poly ADP ribose polymerase; Biology; Genetics; Polymerase","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007076056,0.0002960325,0.0004648702,0.0001978817,0.0001958304,0.0004482658,0.0001889343,0.0003346252,0.000834155],"category_scores_gemma":[0.00099054,0.0002158848,0.0001903855,0.0001477105,0.0003189119,0.0002894414,0.0001545773,0.000645084,0.0001421762],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004586424,"about_ca_system_score_gemma":0.0005546504,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005052176,"about_ca_topic_score_gemma":0.001298532,"domain_scores_codex":[0.9997827,0.00007862538,0.00001063664,0.00005880614,0.00004155331,0.000027579],"domain_scores_gemma":[0.9995373,0.0001296859,0.000133756,0.00003798036,0.00003480159,0.0001263736],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.1351551,0.00589615,0.4607495,0.0002901788,0.0006471588,0.0004891962,0.0005107695,0.003051848,0.2384999,0.0001733722,0.001115114,0.1534218],"study_design_scores_gemma":[0.03034022,0.1727226,0.7130207,0.00003744523,0.0008852634,0.001986088,0.0002601429,0.008028952,0.06766845,0.0002925135,0.004722463,0.00003503569],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9992926,0.0002577495,0.0001106183,0.00003371185,0.000003858946,0.00005061034,0.00008887873,0.000006782744,0.0001552395],"genre_scores_gemma":[0.9987249,0.00009726666,0.0004539536,0.0000943652,0.0000112388,0.00004911329,0.0003684327,0.000003600104,0.0001973283],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.000834155,"threshold_uncertainty_score":0.003742278,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2764266495127368,"score_gpt":0.565274280103611,"score_spread":0.2888476305908742,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}